vs
Side-by-side financial comparison of Ameriprise Financial (AMP) and Bausch Health Companies Inc. (BHC). Click either name above to swap in a different company.
Ameriprise Financial is the larger business by last-quarter revenue ($4.9B vs $2.8B, roughly 1.7× Bausch Health Companies Inc.). Ameriprise Financial runs the higher net margin — 18.7% vs -3.7%, a 22.4% gap on every dollar of revenue. On growth, Bausch Health Companies Inc. posted the faster year-over-year revenue change (9.3% vs 9.0%). Over the past eight quarters, Bausch Health Companies Inc.'s revenue compounded faster (14.0% CAGR vs 5.5%).
Ameriprise Financial, Inc., through its subsidiaries, provides various financial products and services to individual and institutional clients in the United States and internationally. It operates through four segments: Advice & Wealth Management, Asset Management, Retirement & Protection Solutions, and Corporate & Other. The Advice & Wealth Management segment provides financial planning and advice; brokerage products and services for retail and institutional clients; discretionary and non-di...
Bausch Health Companies Inc. is a global, diversified American-Canadian pharmaceutical company. Its global corporate headquarters are located in Laval, Quebec, Canada, and its U.S. headquarters are in Bridgewater, New Jersey. It develops, manufactures and markets a range of pharmaceutical products in gastroenterology, hepatology, neurology, dermatology, dentistry, medical aesthetics, and international pharmaceuticals. Bausch Health manufactures and markets branded pharmaceuticals, generic ph...
AMP vs BHC — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $4.9B | $2.8B |
| Net Profit | $915.0M | $-103.0M |
| Gross Margin | — | — |
| Operating Margin | — | 17.0% |
| Net Margin | 18.7% | -3.7% |
| Revenue YoY | 9.0% | 9.3% |
| Net Profit YoY | 57.0% | -205.1% |
| EPS (diluted) | — | $-0.30 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $4.9B | — | ||
| Q4 25 | $5.0B | $2.8B | ||
| Q3 25 | $4.9B | $2.7B | ||
| Q2 25 | $4.5B | $2.5B | ||
| Q1 25 | $4.5B | $2.3B | ||
| Q4 24 | $4.6B | $2.6B | ||
| Q3 24 | $4.6B | $2.5B | ||
| Q2 24 | $4.4B | $2.4B |
| Q1 26 | $915.0M | — | ||
| Q4 25 | $1.0B | $-103.0M | ||
| Q3 25 | $912.0M | $179.0M | ||
| Q2 25 | $1.1B | $148.0M | ||
| Q1 25 | $583.0M | $-58.0M | ||
| Q4 24 | $1.1B | $98.0M | ||
| Q3 24 | $511.0M | $-85.0M | ||
| Q2 24 | $829.0M | $10.0M |
| Q1 26 | — | — | ||
| Q4 25 | 25.6% | 17.0% | ||
| Q3 25 | 24.0% | 23.1% | ||
| Q2 25 | 30.1% | 17.5% | ||
| Q1 25 | 15.3% | 12.2% | ||
| Q4 24 | 29.1% | 21.8% | ||
| Q3 24 | 14.1% | 12.7% | ||
| Q2 24 | 23.9% | 16.2% |
| Q1 26 | 18.7% | — | ||
| Q4 25 | 20.0% | -3.7% | ||
| Q3 25 | 18.6% | 6.7% | ||
| Q2 25 | 23.6% | 5.8% | ||
| Q1 25 | 13.0% | -2.6% | ||
| Q4 24 | 23.0% | 3.8% | ||
| Q3 24 | 11.2% | -3.4% | ||
| Q2 24 | 18.9% | 0.4% |
| Q1 26 | — | — | ||
| Q4 25 | $10.39 | $-0.30 | ||
| Q3 25 | $9.33 | $0.48 | ||
| Q2 25 | $10.73 | $0.40 | ||
| Q1 25 | $5.83 | $-0.16 | ||
| Q4 24 | $10.57 | $0.24 | ||
| Q3 24 | $5.00 | $-0.23 | ||
| Q2 24 | $8.02 | $0.03 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $8.3B | $1.3B |
| Total DebtLower is stronger | $3.3B | $20.8B |
| Stockholders' EquityBook value | $355.9B | $-554.0M |
| Total Assets | $184.4B | $26.4B |
| Debt / EquityLower = less leverage | 0.01× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $8.3B | — | ||
| Q4 25 | — | $1.3B | ||
| Q3 25 | — | $1.3B | ||
| Q2 25 | — | $1.7B | ||
| Q1 25 | — | $1.1B | ||
| Q4 24 | — | $1.2B | ||
| Q3 24 | — | $719.0M | ||
| Q2 24 | — | $595.0M |
| Q1 26 | $3.3B | — | ||
| Q4 25 | — | $20.8B | ||
| Q3 25 | — | $21.0B | ||
| Q2 25 | — | $21.7B | ||
| Q1 25 | — | $21.5B | ||
| Q4 24 | — | $21.6B | ||
| Q3 24 | — | $21.5B | ||
| Q2 24 | — | $21.7B |
| Q1 26 | $355.9B | — | ||
| Q4 25 | $6.5B | $-554.0M | ||
| Q3 25 | $6.5B | $-565.0M | ||
| Q2 25 | $6.1B | $-764.0M | ||
| Q1 25 | $5.4B | $-1.2B | ||
| Q4 24 | $5.2B | $-1.3B | ||
| Q3 24 | $5.7B | $-1.2B | ||
| Q2 24 | $5.0B | $-1.2B |
| Q1 26 | $184.4B | — | ||
| Q4 25 | $190.9B | $26.4B | ||
| Q3 25 | $190.1B | $26.8B | ||
| Q2 25 | $184.9B | $27.3B | ||
| Q1 25 | $179.1B | $26.4B | ||
| Q4 24 | $181.4B | $26.5B | ||
| Q3 24 | $186.0B | $26.5B | ||
| Q2 24 | $179.7B | $26.5B |
| Q1 26 | 0.01× | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $495.0M |
| Free Cash FlowOCF − Capex | — | $403.0M |
| FCF MarginFCF / Revenue | — | 14.4% |
| Capex IntensityCapex / Revenue | — | 3.3% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $1.0B |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $2.7B | $495.0M | ||
| Q3 25 | $2.2B | $405.0M | ||
| Q2 25 | $1.8B | $289.0M | ||
| Q1 25 | $1.7B | $211.0M | ||
| Q4 24 | $383.0M | $601.0M | ||
| Q3 24 | $3.0B | $405.0M | ||
| Q2 24 | $1.7B | $380.0M |
| Q1 26 | — | — | ||
| Q4 25 | $2.6B | $403.0M | ||
| Q3 25 | $2.2B | $314.0M | ||
| Q2 25 | $1.7B | $190.0M | ||
| Q1 25 | $1.6B | $96.0M | ||
| Q4 24 | $325.0M | $495.0M | ||
| Q3 24 | $3.0B | $334.0M | ||
| Q2 24 | $1.7B | $302.0M |
| Q1 26 | — | — | ||
| Q4 25 | 52.0% | 14.4% | ||
| Q3 25 | 44.1% | 11.7% | ||
| Q2 25 | 38.4% | 7.5% | ||
| Q1 25 | 36.8% | 4.2% | ||
| Q4 24 | 7.0% | 19.3% | ||
| Q3 24 | 65.8% | 13.3% | ||
| Q2 24 | 38.8% | 12.6% |
| Q1 26 | — | — | ||
| Q4 25 | 0.9% | 3.3% | ||
| Q3 25 | 0.9% | 3.4% | ||
| Q2 25 | 0.8% | 3.9% | ||
| Q1 25 | 0.8% | 5.1% | ||
| Q4 24 | 1.2% | 4.1% | ||
| Q3 24 | 1.1% | 2.8% | ||
| Q2 24 | 0.4% | 3.2% |
| Q1 26 | — | — | ||
| Q4 25 | 2.65× | — | ||
| Q3 25 | 2.42× | 2.26× | ||
| Q2 25 | 1.66× | 1.95× | ||
| Q1 25 | 2.89× | — | ||
| Q4 24 | 0.36× | 6.13× | ||
| Q3 24 | 5.96× | — | ||
| Q2 24 | 2.07× | 38.00× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMP
| Management and financial advice fees | $2.9B | 60% |
| Other | $872.0M | 18% |
| Distribution fees | $563.0M | 12% |
| Premiums, policy and contract charges | $341.0M | 7% |
| Other revenues | $166.0M | 3% |
BHC
| Bausch Lomb | $1.4B | 50% |
| Salix Segment | $693.0M | 25% |
| International Rx | $306.0M | 11% |
| Diversified Segment | $255.0M | 9% |
| Solta Medical Segment | $137.0M | 5% |
